We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Chromosomal Amplifications and Deletions Characterize Germ Line Tumors

By Gerald M. Slutzky, PhD
Posted on 14 Dec 2016
Print article
Image: A micrograph of a seminoma, a common germ cell tumor. Tumor cells show a fried egg-like appearance (Photo courtesy of Wikimedia Commons).
Image: A micrograph of a seminoma, a common germ cell tumor. Tumor cells show a fried egg-like appearance (Photo courtesy of Wikimedia Commons).
Cancer researchers have identified several distinct genomic features underlying the origin of germ cell tumors and that are associated with the chemosensitivity of this type of cancer, as well as changes that occur during the rare progression to chemoresistance.

Germ cell tumors (GCTs) are derived from germ cells and occur most frequently in the testes. GCTs are histologically heterogeneous and are usually curable with chemotherapy, even after metastasis. Gains of chromosome arm 12p and aneuploidy are nearly universal in GCTs but specific somatic genomic features driving tumor initiation, chemosensitivity, and progression have not been completely characterized.

Investigators at the Dana-Farber Cancer Institute (Boston, MA, USA) used clinical whole-exome and transcriptome sequencing to analyze 59 precursor, primary (testicular and mediastinal), and chemoresistant metastatic human GCTs obtained from 49 patients

They reported in the December 1, 2016, issue of the journal Nature that the primary somatic feature of GCTs was the highly recurrent chromosome arm level amplifications and reciprocal deletions (reciprocal loss of heterozygosity) - variations that were significantly enriched in GCTs compared to 19 other cancer types. These tumors also acquired KRAS mutations during the development from precursor to primary disease, and primary testicular GCTs (TGCTs) expressed uniformly wild type and fully functional p53 tumor suppressor genes.

Detailed examination of samples from germ cell tumors that had developed drug resistance revealed that as the cancers progressed, they showed further increases in chromosomal abnormalities seen in all the tumors.

"The gain and loss of DNA copies shows that the tumors' chromosomes are profoundly deranged," said senior author Dr. Eliezer Van Allen, assistant professor of medicine at the Dana-Farber Cancer Institute, "and represents a hallmark feature we had not noticed before. This abnormality may be linked to the development of germ cell tumors and cause them to be sensitive to chemotherapy, but exactly how it does so remains to be discovered."

Related Links:
Dana-Farber Cancer Institute

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.